高剂量伏美替尼成功挽救治疗1例携带EGFR外显子20插入突变的肺腺癌患者 - Suppr

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

作者信息

Jiang Weizhen, Sha Min, Chen Cheng

机构信息

Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China.

出版信息

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

DOI:10.1097/MJT.0000000000001504

PMID:35482932

Abstract

摘要

相似文献

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.

Medicine (Baltimore). 2023 Dec 29;102(52):e36667. doi: 10.1097/MD.0000000000036667.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient  with EGFR Exon 20 Insertion Mutantion].

Zhongguo Fei Ai Za Zhi. 2024 Mar 20;27(3):241-244. doi: 10.3779/j.issn.1009-3419.2024.102.11.

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.

Lung Cancer. 2020 Oct;148:175-176. doi: 10.1016/j.lungcan.2020.08.013. Epub 2020 Aug 21.

A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.

Lung Cancer. 2021 Feb;152:193-195. doi: 10.1016/j.lungcan.2020.12.014. Epub 2020 Dec 16.

A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.

Gan To Kagaku Ryoho. 2021 Jun;48(6):845-847.

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.

Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.

Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.

Chemotherapy. 2022;67(4):248-252. doi: 10.1159/000525623. Epub 2022 Jun 28.

引用本文的文献

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.

Int J Mol Sci. 2023 Sep 12;24(18):13972. doi: 10.3390/ijms241813972.

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.

Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z.

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

J Cancer Res Clin Oncol. 2023 Aug;149(10):7729-7742. doi: 10.1007/s00432-023-04726-x. Epub 2023 Apr 1.

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.

Front Pharmacol. 2023 Feb 3;14:1053805. doi: 10.3389/fphar.2023.1053805. eCollection 2023.

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?

Lung Cancer (Auckl). 2022 Oct 25;13:67-73. doi: 10.2147/LCTT.S385437. eCollection 2022.

[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)].

Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):627-641. doi: 10.3779/j.issn.1009-3419.2022.101.47.

"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Front Oncol. 2022 Jul 8;12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

作者信息

Jiang Weizhen, Sha Min, Chen Cheng

机构信息

Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China.

出版信息

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

DOI:10.1097/MJT.0000000000001504

PMID:35482932

Abstract

摘要

相似文献

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

Medicine (Baltimore). 2023 Dec 29;102(52):e36667. doi: 10.1097/MD.0000000000036667.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient  with EGFR Exon 20 Insertion Mutantion].

Zhongguo Fei Ai Za Zhi. 2024 Mar 20;27(3):241-244. doi: 10.3779/j.issn.1009-3419.2024.102.11.

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.

Lung Cancer. 2020 Oct;148:175-176. doi: 10.1016/j.lungcan.2020.08.013. Epub 2020 Aug 21.

A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.

Lung Cancer. 2021 Feb;152:193-195. doi: 10.1016/j.lungcan.2020.12.014. Epub 2020 Dec 16.

A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.

Gan To Kagaku Ryoho. 2021 Jun;48(6):845-847.

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.

Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.

Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.

Chemotherapy. 2022;67(4):248-252. doi: 10.1159/000525623. Epub 2022 Jun 28.

引用本文的文献

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.

Int J Mol Sci. 2023 Sep 12;24(18):13972. doi: 10.3390/ijms241813972.

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.

Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z.

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

J Cancer Res Clin Oncol. 2023 Aug;149(10):7729-7742. doi: 10.1007/s00432-023-04726-x. Epub 2023 Apr 1.

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.

Front Pharmacol. 2023 Feb 3;14:1053805. doi: 10.3389/fphar.2023.1053805. eCollection 2023.

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?

Lung Cancer (Auckl). 2022 Oct 25;13:67-73. doi: 10.2147/LCTT.S385437. eCollection 2022.

[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)].

Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):627-641. doi: 10.3779/j.issn.1009-3419.2022.101.47.

"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Front Oncol. 2022 Jul 8;12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献